These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31054132)

  • 21. Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.
    Hamersky CM; Fridman M; Gamble CL; Iyer NN
    Diabetes Ther; 2019 Jun; 10(3):865-890. PubMed ID: 31054132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.
    Evans M; Engberg S; Faurby M; Fernandes JDDR; Hudson P; Polonsky W
    Diabetes Obes Metab; 2022 Mar; 24(3):377-390. PubMed ID: 34779107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Systematic Review of Insulin Adherence Measures in Patients with Diabetes.
    Stolpe S; Kroes MA; Webb N; Wisniewski T
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1224-1246. PubMed ID: 27783551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.
    Giorgino F; Penfornis A; Pechtner V; Gentilella R; Corcos A
    Patient Prefer Adherence; 2018; 12():707-719. PubMed ID: 29765207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
    Tuchscherer RM; Thompson AM; Trujillo JM
    Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-adherence to basal insulin among patients with type 2 diabetes in a US managed care population: Results from a patient survey.
    Stephenson JJ; Raval AD; Kern DM; Bae JP
    Diabetes Obes Metab; 2018 Nov; 20(11):2700-2704. PubMed ID: 29931727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
    Li Q; Ganguly R; Ganz ML; Gamble C; Dang-Tan T
    Diabetes Ther; 2018 Jun; 9(3):1279-1293. PubMed ID: 29744818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.
    Carls GS; Tan R; Zhu JY; Tuttle E; Yee J; Edelman SV; Polonsky WH
    Obes Sci Pract; 2017 Sep; 3(3):342-351. PubMed ID: 29071110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.
    Carls GS; Tuttle E; Tan RD; Huynh J; Yee J; Edelman SV; Polonsky WH
    Diabetes Care; 2017 Nov; 40(11):1469-1478. PubMed ID: 28801475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control.
    Edelman SV; Polonsky WH
    Diabetes Care; 2017 Nov; 40(11):1425-1432. PubMed ID: 28801473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.
    Perez-Nieves M; Ivanova JI; Hadjiyianni I; Zhao C; Cao D; Schmerold L; Kalirai S; King S; DeLozier AM; Birnbaum HG; Peyrot M
    Curr Med Res Opin; 2017 Oct; 33(10):1833-1842. PubMed ID: 28604111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes.
    Sambamoorthi U; Garg R; Deb A; Fan T; Boss A
    Curr Med Res Opin; 2017 Jul; 33(7):1309-1316. PubMed ID: 28393573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment adherence in patients with type 2 diabetes mellitus correlates with different coping styles, low perception of self-influence on disease, and depressive symptoms.
    Kokoszka A
    Patient Prefer Adherence; 2017; 11():587-595. PubMed ID: 28360512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study.
    Nishimura A; Harashima SI; Fukushige H; Wang Y; Liu Y; Hosoda K; Inagaki N
    Diabetes Ther; 2017 Apr; 8(2):385-399. PubMed ID: 28236272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
    Kalirai S; Duan R; Liu D; Reed BL
    J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
    Lin J; Lingohr-Smith M; Fan T
    Clinicoecon Outcomes Res; 2017; 9():19-29. PubMed ID: 28053550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.
    Hadjiyianni I; Desai U; Suzuki S; Ivanova JI; Cao D; Kirson NY; Chida D; Enloe C; Birnbaum HG; Perez-Nieves M
    Diabetes Ther; 2017 Feb; 8(1):149-166. PubMed ID: 27913984
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.